Biomaterials
Recent news:
MuscleMatrix and their hydrogel scaffold for muscle loss injuries is part of LSEC’s 2nd cohort of Venture Grant startups.
Researchers in Professor Phillip Messersmith’s lab have demonstrated that treatment with DPCA, an enzyme inhibitor molecule shown to trigger regeneration in mammals, can protect against and repair colon damage in a mouse model of colitis. This work suggests that short-term use of this small molecule drug could someday provide a restorative therapy for patients with IBD — and a path to remission.